|
| Kemwell plans biopharma plant in city |
| BS Reporter / Chennai/ Bangalore Jun 09, 2009, 00:01 IST |
|
In tie-up with German firm Boehringer Ingelheim.
Kemwell, a provider of contract manufacturing and development services for pharmaceutical products globally, is building a biopharmaceutical manufacturing plant in Bangalore. The
Rs 300-crore Bangalore-based company is planning to invest $50 million (about Rs 235 crore) on this facility, and has formed a strategic alliance with German pharmaceutical firm Boehringer Ingelheim for technical and marketing collaboration. Under this, Boehringer Ingelheim will provide technical know-how and marketing support to Kemwell for its contract manufacturing services.
Speaking to Business Standard after the ground-breaking ceremony for the new plant here today, Anurag Mathur, vice-president, Kemwell said the 15,000 sq mt greenfield facility is being designed for process development, fermentation, purification and formulation of biologicals for clinical studies. The plant will consist of a cGMP (current Good Manufacturing Practices)-compliant drug manufacturing facility and, a sterile fill and finish facility for drugs. It will house process development laboratories to support production of protein therapeutics.
Biopharmaceuticals are drugs produced using biosynthesis as opposed to drugs manufactured using chemical synthesis. “Biopharmaceuticals are growing faster than the pharmaceuticals market because they address the therapeutic needs, which otherwise cannot be treated,” said Rolf G Werner, corporate senior vice-president, corporate division biopharmaceuticals, Boehringer Ingelheim. Examples for biopharmaceuticals are insulin, erythropoietin, factor 8, monoclonal antibodies and antibody mimetics.
Globally, Biopharmaceuticals is a $70 billion market, growing annually at the rate of 16 per cent, whereas chemical pharmaceuticals, with a market size of $600 billion is growing at 8 per cent. In India, biopharmaceuticals including vaccines is a $1 billion sector. The advantage of biopharmaceuticals over chemical drugs is that the former are considered to have fewer side effects and they can be developed quickly.
“Globally, there are over 400 biopharmaceuticals in various stages of clinical development. In this rapidly-growing sector, manufacturing of cGMP clinical trial material is a challenge. Boehringer Ingelheim will support Kemwell with process IP and technological know-how for the economic and high quality cGMP manufacturing,” said Werner.
Kemwell has four facilities in Bangalore and one in Sweden manufacturing chemical pharmaceuticals like tablets, capsules, liquid orals, ointments, gels and creams for global brands. Its customers include GSK, Pfizer, Novartis, Johnson and Johnson. With the opening of the new plant in Bangalore, the company is entering the biopharmaceuticals manufacturing space which is largely untapped in India. The company aims to target European countries and the US which are the major markets for biopharmaceuticals.
Headquartered in Ingelheim, Germany, Boehringer Ingelheim is a Euro 11 billion pharmaceutical company with presence in 47 countries.
|
|
|
|
|
|
|
|
|
|
 Read Business news in |  |
|
|
|
|
|
|
Advertisements |
|
|
|
|
|
|
|
|
|
|
Content Guide
